Compare XPOF & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | ARCT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 189.9M |
| IPO Year | 2021 | 2019 |
| Metric | XPOF | ARCT |
|---|---|---|
| Price | $5.85 | $7.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $8.13 | ★ $27.70 |
| AVG Volume (30 Days) | ★ 909.3K | 463.0K |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.83 | $5.85 |
| 52 Week High | $11.14 | $24.14 |
| Indicator | XPOF | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 48.18 |
| Support Level | $5.37 | $6.90 |
| Resistance Level | $6.18 | $7.88 |
| Average True Range (ATR) | 0.32 | 0.35 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 57.93 | 45.88 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.